KALA BIO, Inc. (KALA): restructuring charge — KALA BIO Phase 2b trial fails; KPI-012 development halted; workforce cut 51%

KALA BIO, Inc.

CHASE Phase 2b trial of KPI-012 for PCED did not meet primary endpoint of complete healing at Week 8; secondary endpoints also failed.
Company ceases development of KPI-012 and MSC-S platform; will explore strategic options and engage with secured lender.
Board approved workforce reduction of ~19 employees (~51%); expected to complete in Q4 2025.
KPI-012 was well-tolerated with no treatment-related serious adverse events observed.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

KALA BIO, Inc. announced a restructuring affecting the Company's workforce (approximately 19 employees, or approximately 51%).

Type: restructuring
Affected area: the Company's workforce
Headcount: approximately 19 employees, or approximately 51%

Exact text from the filing

On September 28, 2025, the board of directors (the “Board”) of KALA BIO, Inc. (the “Company”) determined to cease development of KPI-012 and its mesenchymal stem cell secretome platform and to take steps to preserve cash as the Company explores its strategic options. In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-094125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.